What are the approved indications for ZEGERID?
ZEGERID Capsules and Powder for Oral Suspension have been approved by the Food and Drug Administration (FDA) for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD); for the short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy; for maintenance of healing of erosive esophagitis (controlled studies do not extend beyond 12 months); for short-term treatment of active duodenal ulcer (4-8 weeks); and for short-term treatment (4-8 weeks) of active benign gastric ulcer.1 ZEGERID 40 mg Powder for Oral Suspension has also been FDA-approved for reduction of risk of upper gastrointestinal bleeding in critically ill patients.2 (The use of ZEGERID in critically ill patients beyond 14 days has not been evaluated.) Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in capsules, 1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent to, and s
